10 news items
Kevzara® (sarilumab) Approved by FDA for the Treatment of Active Polyarticular Juvenile Idiopathic Arthritis (pJIA)
REGN
11 Jun 24
President, Head, Specialty Care at Sanofi. "This milestone highlights our ongoing commitment to bringing medicines to our younger patients living
MAIA Biotechnology Inc (MAIA) Stock Surges as Company Prepares to Present Promising Data at BIO International Convention
CRL
IQV
MAIA
31 May 24
results.InvestorBrandMedia.com does not commit to updating forward-looking statements based on new information or future events. Readers are encouraged to review all public
Update on FDA Priority Review of Dupixent® (dupilumab) for the Treatment of COPD Patients with Type 2 Inflammation
REGN
31 May 24
that the additional analyses strongly support the approval of Dupixent in COPD with evidence of type 2 inflammation, and are committed to working with the FDA
Press Release: Update on FDA priority review of Dupixent for the treatment of COPD patients with type 2 inflammation
REGN
31 May 24
, and are committed to working with the FDA to bring Dupixent to patients living with uncontrolled COPD as quickly as possible
More than $9 Million Awarded to High School Scientists and Engineers at the Regeneron International Science and Engineering Fair 2024
REGN
17 May 24
organization, Society for Science is committed to inform, educate and inspire. Learn more
cks23iw15152htvpm
REGN
17 May 24
organization, Society for Science is committed to inform, educate and inspire. Learn more
5xpj1o6xmsbfgxabwtrdvhh tcqzkxwcyl41fehxsccbrw
REGN
17 May 24
) membership organization, Society for Science is committed to inform, educate and inspire. Learn more
paagimjneaa1kl4rr9fhie18uzl7dk21xedtnz4hzx yjie9
REGN
29 Apr 24
extensive data presentations at ARVO showcase the differentiated efficacy, safety and durability of EYLEA HD, and demonstrate our commitment to advancing
g7i7l6y13w1dpgmrdpongn4184mblpghjyojd1200ho qfltbol02ll
REGN
24 Apr 24
, M.D., Ph.D., Board co-Chair, President and Chief Scientific Officer at Regeneron. "These latest clinical results build on our ongoing commitment
6sph4tvy7eieo8436p6crt0fyewousxxtjbh1vhn26f
ARGX
ATNM
MRNA
28 Mar 24
potential, and commitment to improving patient care that is both rare and invaluable.
Wednesday's biotech sector
- Prev
- 1
- Next